Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals adds former Boston Scientific CFO Daniel Brennan to board

Neutral Impact 2 of 5 leadership

Vertex Pharmaceuticals appointed Daniel Brennan, a former Chief Financial Officer of Boston Scientific, to its board of directors on October 20, 2026, and expanded the board from ten to eleven members. He also joined the Audit and Finance Committee and received a $400,000 restricted stock unit award that vests in October 2027.

Key points

  • Daniel Brennan joined the board on October 20, 2026; board size increased from ten to eleven members.
  • Brennan retired in June 2025 as Executive Vice President and Chief Financial Officer of Boston Scientific, a role he held from January 2014.
  • Brennan received a $400,000 restricted stock unit award vesting in October 2027 and joined the Audit and Finance Committee.
  • The filing reports no related-person transactions requiring disclosure and no arrangement under which Brennan was appointed.

The filing

CompanyVertex Pharmaceuticals (VRTX)
Form8-K, current report
Filed with the SECOct 20, 2026, 4:09 PM ET
Accession number0000875320-26-000278

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.